If a fibrinolytic drug is used for the treatment of acute myocardial infarction, the adverse effect most likely to occur is:
Acute renal failure
Development of antiplatelet antibodies
Encephalitis secondary to liver dysfunction
Hemorrhagic stroke
Bleeding is the most common adverse effect of anticoagulants, antiplatelets and fibrinolytic agents. Bleeding can manifest as hemorrhagic stroke in pts. on fibrinolytics therapy such as- Alteplase, Retaplase, Streptokinase. C/I of Fibrinolytics :- H/O Hemorrhagic Stroke H/O NON Hemorrhagic Stroke (within 1yr) Suspicion of aoic dissection Marked hypeension (SBP>180mm Hg and DBP>110mm Hg) Active internal bleed (Excluding menses)
Hematology